TheraRadar
← Back
Data updated: Jun 28, 2026

NOVA PNEUMA

Pharma

NOVA PNEUMA is a pharmaceutical company focused on Neurology. Key products include ADASUVE.

2012
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

NOVA PNEUMA's Key Drugs

NOVA PNEUMA's core commercial portfolio centers on ADASUVE, spanning Neurology — its most strategically important drugs approved in the last 15 years.

NOVA PNEUMA's Recent FDA Approvals

New NDA/BLA approvals for NOVA PNEUMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

NOVA PNEUMA's Therapeutic Areas

NOVA PNEUMA's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 100%
0 drugs Phase 2: 1

NOVA PNEUMA's Top Competitors

NOVA PNEUMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

NOVA PNEUMA Pipeline Snapshot

NOVA PNEUMA has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.

0
Phase 3
1
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • ADASUVE leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling